健择联合顺铂治疗晚期非小细胞肺癌32例临床观察

Combination chemotherapy with gemictabine and cisplatin in the treatment of 32 cases of advanced non - small cell lung cancer

目的:评价健择与顺铂联合治疗晚期非小细胞肺癌疗效及毒副反应。方法:健择800mg/m2,静脉滴点,第1、8、15天;顺铂30mg/m2,静脉滴点,第1～3天。每28天为一周期。每例患者至少完成2周期化疗方可评价疗效。结果;全组共32例。其中初治病例12例,复治疗病例20例。总有效率为37.5％（12/32）,中位缓解期为4个月,其中初治患者有效率为50.0％（6/12）,而复治患者的有效率为30.0％（6/20）。本方案主要的副反应是胃肠道反应（34.38％）和血液学毒性,Ⅲ/Ⅳ级的白细胞、血小板降低发生率分别为34.38％和28.13％,谷丙转氨酶升高发生率为12.50％。结论:健择联合顺铂方案治疗NSCLC有较好的疗效,化疗毒性可耐受。

Objective:To evaluate the efficacy and adverse reactions of gemcitabine (GEM) and cisplatin (FDD) in the treatment of advanced non-small cell lung cancer(NSCLC) .Methods: 32 patients with advanced NSCLC were treated with GEM plus DDP. GEM was given at a dose of 800/m2 on days 1, 8 and 15; DDP 30mg/m2 on day 1 to 3. The schedule was repeated every 28 days, with at least two cycles.Results:The overall response rate was 37.50% (12/32) and 50.00% (6/12) for previously untreated patients and 30.00% (6/20) for pretreated patients respectively. The median response time was 4 months. The main adverse reactions were nausea/vomiting(Ⅲ/Ⅳ grade: 34.38% ) and hematologic toxicity. The prevalence of grade IE and IV leukopenia and thrombocytopenia was 34.38% and 28.13% respectively. Transient elevations of hepatic transaminases were seen in 12.50% of patients . No fatal complication was observed in this study. Conclusion: The GEM plus FDD combination is a highly effective regimen for patients with advanced NSCLC, with a manageable toxicity.